In-Vitro Fertilization Market Size, Trends, Share, Report By 2032

The global in-vitro fertilization market reached USD 25 billion in 2022 and is expected to hit around USD 59.45 billion by 2032, poised to grow at a noteworthy CAGR of 9.10% from 2023 to 2032.

Key Points:

By Procedure Type, the frozen non-donor segment has accounted largest revenue share of over 47.4% in 2022.
By End-use, the fertility clinics segment has generated highest revenue share of over 79.9% in 2022.
By instruments, the culture media segment has dominated the market with the revenue share of over 41.3% in 2022.
Europe region has captured revenue share of around 38% in 2022.

The rising infertility among women, declining fertility rates in male, increasing median age of first time mothers, and rising adoption of advanced in-vitro fertilization techniques are the major factors that augments the growth of the global in-vitro fertilization market. The According to the United Nations World Fertility Report 2019,the adolescent fertility rate decreased by over 50% between 1990 to 1995 and 2015 to 2020. Moreover, the Hebrew University of Jerusalem stated that the sperm count in men have declined more than 50% over the last 40 years. Thus, the declining fertility rates among the population are the major driver of the in-vitro fertilization market. Furthermore, the rising medical tourism across the globe is another factor that propels the market growth.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1501

Report Highlights

Based on the product type, the frozen non-donor is estimated to be the most opportunistic segment during the forecast period. This is attributed to the rising awareness regarding the benefits of the frozen non-donor cycle such as low cost, easy transfer, and low level of stress. The adoption of this cycle is gaining rapid traction among the women and hence is expected to grow at a significant pace during the forecast period.
Based on the end user, the fertility clinics segment dominated the market in 2020. This is attributed to the increased popularity of such clinics among the people, specialized infertility related services offered, and increased penetration of fertility clinics across the globe. Hence, this segment is expected to sustain its significance throughout the forecast period.

Regional Snapshot

Europe region accounted largest revenue share 37% in 2020 due to rising medical tourism and legal revisions related to IVF techniques.

Asia Pacific witness highest CAGR during the forecast period 2021 to 2030. Asia Pacific is witnessing a decline in the fertility rates among both the sexes. Rising pollution levels in the region owing to the rising industrialization and urbanization. Moreover, changing lifestyle, changing consumption habits, and rising consumption of alcohol are the factors that are contributing towards the rising infertility. According to the Australian Institute of Health and Welfare, the median age of the first time mothers in Australia grew from 27.9 years to 31.9 years from 2009 to 2019. Moreover, the rising awareness regarding the in-vitro fertilization treatments and rising healthcare expenditure is fueling the growth of the Asia Pacific in-vitro fertilization market.

North America is estimated to be the most opportunistic market during the forecast period. This is attributed to the increasing median age of the first time mothers, rising prevalence of polycystic ovary syndrome, and delayed marriages in the region. The increased awareness regarding the advanced fertilization techniques coupled with increased healthcare expenditure, improved reimbursement policies, and growing number of fertility clinics are the crucial factors that are expected to propel the growth of the in-vitro fertilization market.

Table of Contents

Scope of the In Vitro Fertilization Market

Report Coverage	Details
Market Size	US$ 59.45 Billion by 2032
Growth Rate	CAGR of 9.10% from 2023 to 2032
Largest Market	Europe
Fastest Growing Market	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Product, End User, Region

Vitro Fertilization Market Dynamics

Driver

Increasing median age of the first time mothers

The women now-a-days are preferring their career over starting a family. The increased government focus on women empowerment and women education had resulted in the increased participation of women in workforce. This resulted in delay in marriages, delayed pregnancy, and surge in the usage of contraceptives. All these factors have significantly contributed toward a rise in the median age of the first time mothers. Therefore, the global in-vitro fertilization market is expected to gain rapid traction during the forecast period.

Restraints

High costs involved

A high cost is involved in acquiring the in-vitro fertilization treatment. The low affordability especially in the low and middle income countries, lack of awareness regarding the reimbursement policies, and lack of proper healthcare infrastructure are the major factors that may hinder the market growth in the forthcoming years.

Opportunity

Rising developmental strategies by the key market players

The market players are constantly engaging in strategies like partnerships, collaborations, and new product launches. For instance, in January 2021, Merck KGaA and Royal Philips entered into a partnership for the development of digital solution for providing personalized treatment for fertility.The various developmental strategies like product launches, acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Challenges

Increasing age of women leads to reduced efficacy of fertility treatment

The delay marriages and delayed pregnancies coupled with growing age leads to complications in getting pregnant. Women of age 35 years or more have higher chances of having a miscarriage and stillbirth. Therefore, the declining efficacy of the fertility treatment due to the aging is a major threat to the market.

Key Market Developments

In January 2021, Merck KGaA and Royal Philips entered into a partnership for the development of digital solution for providing personalized treatment for fertility.
In January 2020, Merck KGaA acquired the market authorization for its GONALI-f pen from the European Commission.
In 2020, Fujifilm Irvine Scientific launched a vitrification media solution named Vit Kit-NX.
In 2020, Genea Ltd. Hamilton Throne Ltd. collaborated to commercialize fertility products of Genea Ltd. in North America.

In-Vitro Fertilization Market Companies

AmbroiseParé Group
Amedes MVZ Cologne GmbH
AMP Center St Roch
AVA Clinic Scanfert
Bangkok IVF center
Betamedics
Biofertility Center
Bloom Fertility and Healthcare
Bloom Fertility Center
Bourn Hall Fertility Center

Segments Covered in the Report

By Product Type

Fresh Donor
Fresh Non-Donor
Frozen Donor
Frozen Non-Donor

By End User

Fertility Clinics
Surgical Centers
Hospitals
Research Institutes

By Product

Equipment
- Sperm Analyzer Systems
- Imaging Systems
- Ovum Aspiration Pumps
- Micromanipulator Systems
- Incubators
- Gas Analyzers
- Laser Systems
- Cryosystems
- Sperm Separation Devices
- IVF Cabinets
- Anti-vibration Tables
- Witness Systems
- Other Equipments
Reagents & Media
- Cryopreservation Media
- Embryo Culture Media
- Ovum Processing Media
- Sperm Processing Media
Accessories

By Type

Conventional IVF
IVF with ICSI
IVF with Donar Eggs
Others

By Instrument

Culture Media
Disposable Devices
Capital Equipment

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa